% Expired Patents = 76.2

CIPO Patents = 2

EPO Patents = 2

Forward Citations = 628

Loading Chart...

2 inventors (with patents filed for the assignee):

Michael S Kopreski (21 out of 40 patents)

Christopher D Gocke (5 out of 25 patents)

Mike Kopreski (0 patent)

21 patents: Sort by Forward Citations

1. 8809020 - Method enabling the use of extracellular ribonucleic acid (RNA) extracted from plasma or serum to detect, monitor or evaluate cancer or premalignant conditions (2014-08-19),

2. 8440396 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2013-05-14),

3. 8163524 - Comparative analysis of extracellular RNA species (2012-04-24),

4. 8043835 - Methods for detecting and monitoring cancer using extracellular RNA (2011-10-25),

5. 8030031 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2011-10-04),

6. 7972817 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2011-07-05),

7. 7968317 - Detection of 5T4 RNA in plasma and serum (2011-06-28),

8. 7932061 - Method enabling the use of extracellular ribonucleic acid (RNA) extracted from plasma of serum to detect, monitor or evaluate cancer or premalignant conditions (2011-04-26),

9. 7910336 - Method for detection of hTR and hTERT telomerase-associated RNA in plasma or serum (2011-03-22),

10. 7785842 - Comparative analysis of extracellular RNA species (2010-08-31),

11. 7767423 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2010-08-03),

12. 7767422 - Detection of 5T4 RNA in plasma and serum (2010-08-03),

13. 7767390 - Methods for evaluating drug-resistance gene expression in the cancer patient (2010-08-03),

14. 7732141 - Methods for evaluating drug-resistance gene expression in the cancer patient (2010-06-08),

15. 7709233 - Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer (2010-05-04),

Company Overview

Oncomedx, Inc. is a biotechnology company based in Long Valley, NJ, specializing in the development of innovative diagnostic solutions for cancer. The organization focuses on leveraging advanced genomic technologies to enhance cancer detection and treatment strategies. By integrating cutting-edge research with clinical applications, Oncomedx aims to improve patient outcomes through personalized medicine. Their commitment to advancing cancer diagnostics positions them as a key player in the evolving landscape of oncology healthcare.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

21 Patents

#2 in Long Valley, NJ

#602 in New Jersey

#15,695 in US

#29,961 in the World

Long Valley, NJ, United States of America

Oncomedx, Inc.

Forward Citations = 628

2 inventors:

Michael S Kopreski (21 out of 40 patents)

Christopher D Gocke (5 out of 25 patents)

Mike Kopreski (0 patent)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Oncomedx, Inc.. Retrieved from https://idiyas.com/company/oncomedx

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (CIPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

2 patents (EPO):

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]